While current therapies for AD primarily focus on reducing Aβ or tau pathology, such as monoclonal antibodies (aducanumab and lecanemab) and tau aggregation inhibitors, these approaches have shown limited efficacy and are often associated with adverse effects. This evidence concerns the gene MAPT and Alzheimer disease.